Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Aptose Announces Results from Annual and Special Meeting of Shareholders

European Hematology Association Congress (EHA 2025)

Jun 12, 2025 • 5:00 pm - 6:15 pm CEST

2025 Annual and Special Meeting of Shareholders

May 27, 2025 • 10:00 am EDT